Systemic Lupus Erythematosus - Pipeline Review, H1 2018

Publication ID:
GMD0518129

Publication Date:
May 31, 2018

Pages:
446

Publisher:
Global Markets Direct

Region:
Global [1]

$2,000.00

Publication License Type *
- Single User License (PDF), $2,000.00
- Site License (PDF), $4,000.00
- Global License (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
**Description:**
Systemic Lupus Erythematosus - Pipeline Review, H1 2018

**Summary**


"Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia."

**Report Highlights**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 10, 30, 25, 41, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 8 and 1 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology).

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents:
Table of Contents
Table of Contents 2
Systemic Lupus Erythematosus - Pipeline by Corestem Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Co, H1 2018
Systemic Lupus Erythematosus - Pipeline by Epsilon-3 Bio Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Galapagos NV, H1 2018
Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Genosco Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Genovax Srl, H1 2018
Systemic Lupus Erythematosus - Pipeline by Gilead Sciences Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Idorsia Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immunogenetics AG, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immunomedics Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immunwork Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Invion Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Janus Biotherapeutics Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H1 2018
Systemic Lupus Erythematosus - Pipeline by K-Stemcell Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Kezar Life Sciences Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H1 2018
Systemic Lupus Erythematosus - Pipeline by LSK BioPartners Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H1 2018
Systemic Lupus Erythematosus - Pipeline by Merck & Co Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H1 2018
Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Nektar Therapeutics, H1 2018
Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H1 2018
Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Novartis AG, H1 2018
Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H1 2018
Systemic Lupus Erythematosus - Pipeline by Omeros Corp, H1 2018
Systemic Lupus Erythematosus - Pipeline by Pfizer Inc, H1 2018

List of Figures
List of Figures
Number of Products under Development for Systemic Lupus Erythematosus, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Companies Mentioned:
AbbVie Inc
ACEA Biosciences Inc
AiCuris GmbH & Co KG
Amgen Inc
Apellis Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Asahi Kasei Pharma Corp
Atlantic Bio Sci LLC
Aurinia Pharmaceuticals Inc
Bio-Path Holdings Inc
Biogen Inc
Biotest AG
Boehringer Ingelheim GmbH
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Carna Biosciences Inc
Celgene Corp
Cells for Cells SA
Corestem Inc
CuraVac Inc
Deltanoid Pharmaceuticals Inc
Domainex Ltd
Eisai Co Ltd
Eli Lilly and Co
Epsilon-3 Bio Ltd
F. Hoffmann-La Roche Ltd
Galapagos NV
Genentech Inc
Genosco Inc
Genovax Srl
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Idorsia Ltd
Immungene AG
Immunomedics Inc
Immunwork Inc
Immupharma Plc
Invion Ltd
Janus Biotherapeutics Inc
Johnson & Johnson
K-Stemcell Co Ltd
Kezar Life Sciences Inc
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
LSK BioPartners Inc
MedAnnex Ltd
MedImmune LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Mount Tam Biotechnologies Inc
Nektar Therapeutics
Neovacs SA
Nippon Chemiphar Co Ltd
Novartis AG
Nuevolution AB
Omeros Corp
Pfizer Inc
Ra Pharmaceuticals Inc
RedHill Biopharma Ltd
Regen BioPharma Inc
Sarepta Therapeutics Inc
SBI Biotech Co Ltd
Takeda Pharmaceutical Co Ltd
TheraMAB LLC
UCB SA
Xencor Inc
XTL Biopharmaceuticals Ltd
Zai Lab Ltd

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless an Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.
Global License (PDF)*

• This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
• Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
• These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.
What is drug pipeline research?
March 20

How to use market research to bring your idea to life?
March 11

How to gain business insights using syndicated market research?
March 10

Source URL: https://www.drugpipeline.net/global-markets-direct/systemic-lupus-erythematosus-pipeline-review-h1-2018

Links
[1] https://www.drugpipeline.net/region/global